In recent trading, shares of Travere Therapeutics Inc (TVTX) have crossed above the average analyst 12-month target price of $17.00, changing hands for $17.59/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..